Equifin (AMEX:II)
Historical Stock Chart
From Jun 2019 to Jun 2024
Ivivi Technologies, Inc. (AMEX: II), a leader in non-invasive,
electrotherapeutic technologies, today announced that management will
discuss the Company's results for its first fiscal quarter ended June
30, 2007, during a conference call scheduled for Tuesday, August 14,
2007 at 4:30 pm ET. The Company's financial results for the first
quarter of fiscal 2008 are scheduled to be released after the market
closes on August 14, 2007 and prior to the conference call.
Shareholders and other interested parties may participate in the
conference call by dialing (877) 407-0782 approximately 5 to 10
minutes before the beginning of the call. International callers should
dial (201) 689-8567. If you are unable to participate, a replay of the
call will be available until midnight on August 28, 2007 by dialing
(877) 660-6853 and using pass code # 286 and conference ID #
251433. International callers should dial (201) 612-7415 and use the
pass codes listed above. The call will also be broadcast live on the
Internet at www.InvestorCalendar.com
and on the Investor Relations section of the Company’s
website www.ivivitechnologies.com.
An archive of the call will also be available on the Company’s
website for 90 days.
About Ivivi Technologies, Inc.
Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology
company focusing on designing, developing and commercializing its
proprietary electrotherapeutic technology platform. Ivivi’s
research and development activities are focused specifically on pulsed
electromagnetic field, or PEMF, technology, which, by creating a
therapeutic electrical current in injured soft tissue, stimulates
biochemical and physiological healing processes to help repair the
injured tissue and reduce related pain and inflammation. The Company’s
Electroceuticals™ have been used in
non-invasive treatments for a wide array of conditions, including
chronic wounds, pain and edema following plastic and reconstructive
surgery and chronic inflammatory disorders.